ATE297755T1 - Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind - Google Patents

Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Info

Publication number
ATE297755T1
ATE297755T1 AT98915471T AT98915471T ATE297755T1 AT E297755 T1 ATE297755 T1 AT E297755T1 AT 98915471 T AT98915471 T AT 98915471T AT 98915471 T AT98915471 T AT 98915471T AT E297755 T1 ATE297755 T1 AT E297755T1
Authority
AT
Austria
Prior art keywords
lactoferrin
allergens
treatment
conditions caused
asthma
Prior art date
Application number
AT98915471T
Other languages
English (en)
Inventor
Ian Kimber
Marie Cumberbatch
Rebecca J Dearman
Orla M Conneely
Pauline Ward
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Application granted granted Critical
Publication of ATE297755T1 publication Critical patent/ATE297755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98915471T 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind ATE297755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (1)

Publication Number Publication Date
ATE297755T1 true ATE297755T1 (de) 2005-07-15

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915471T ATE297755T1 (de) 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Country Status (12)

Country Link
US (1) US20030190303A1 (de)
EP (1) EP0979099B1 (de)
JP (1) JP2001519815A (de)
CN (1) CN1262625A (de)
AT (1) ATE297755T1 (de)
AU (1) AU747385C (de)
CA (1) CA2285960A1 (de)
DE (1) DE69830582T2 (de)
ES (1) ES2245028T3 (de)
IL (1) IL132293A0 (de)
NZ (1) NZ500712A (de)
WO (1) WO1998044940A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL336626A1 (en) * 1997-05-03 2000-07-03 Regents Board Of Methods of preventing and treating traumatic loss of metabolic equlibrium among human beings and animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU782539B2 (en) * 2000-01-14 2005-08-04 Meiji Dairies Corporation Antigen-specific IgE antibody production inhibitors
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
EP2543385A1 (de) 2002-01-21 2013-01-09 NRL Pharma, Inc. Neuartige Analgetika
EP2286827A1 (de) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in der Behandlung maligner Neoplasmen und anderer hyperproliferativer Erkrankungen
AU2003233583A1 (en) 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US20090203586A1 (en) * 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
DK1833495T3 (da) 2005-03-15 2008-06-02 Campina Nederland Holding Bv Dermatologisk anvendelse af mælkeproteiner
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
AU2006300009A1 (en) * 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
US20090130191A1 (en) * 2005-10-27 2009-05-21 Sunstar Inc. Osteoclast Growth Inhibitor, Oral Composition, and Preventive or Therapeutic Agent for Bone Diseases, Containing Liposome-Encapsulated Lactoferrin
CN103002907A (zh) * 2010-04-23 2013-03-27 普若拜特有限公司 湿疹治疗
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
EP3836954B1 (de) 2018-08-13 2025-05-07 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
WO2021116403A1 (en) * 2019-12-11 2021-06-17 N.V. Nutricia Nutritional composition for improving immune fitness
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
IL132293A0 (en) 2001-03-19
DE69830582D1 (de) 2005-07-21
EP0979099A1 (de) 2000-02-16
AU747385C (en) 2003-01-30
CN1262625A (zh) 2000-08-09
WO1998044940A1 (en) 1998-10-15
JP2001519815A (ja) 2001-10-23
AU747385B2 (en) 2002-05-16
ES2245028T3 (es) 2005-12-16
AU6964798A (en) 1998-10-30
EP0979099B1 (de) 2005-06-15
DE69830582T2 (de) 2006-05-04
CA2285960A1 (en) 1998-10-15
US20030190303A1 (en) 2003-10-09
NZ500712A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
DE69830582D1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE296799T1 (de) P38-inhibitoren
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
FI935585A0 (fi) Pyrrolopyrimidiner
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
MY132496A (en) Inhibitors of p38
MY117696A (en) INHIBITORS OF p38
EP1043995A4 (de) INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
DE69729796D1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
DK0841898T3 (da) Topiske sammensætninger, der har forbedret hudfornemmelse
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE69030212D1 (de) Verwendung von Derivaten des 4-Phenyl-1,2,3,4-tetrahydro-1-naphthalenamins zur Behandlung von Psychose, Entzündung und als Immununterdrücker
BRPI0411784A (pt) anticorpos contra interleucina -22 e usos para os mesmos
DE69829866D1 (de) Sklerotische prothese für die behandlung von altersweitsichtigkeit und anderen augenkrankheiten
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE60238149D1 (de) Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
NO971902L (no) Bindingsmidler til CD23
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
YU113391A (sh) 2,4 i 2,5 substituirani piridin-n oksidi i postupak za njihovu proizvodnju
NO996287D0 (no) Chalkoner med antiproliferativ aktivitet
DE69524093D1 (de) Kombination von prokoagulans und cytokin oder induktor seiner produktion für die behandlung von tumoren
NO20010940D0 (no) TAN-1057 derivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties